MX2019006354A - Composicion de microparticulas derivadas de globulos rojos (rmp) y metodos de uso. - Google Patents

Composicion de microparticulas derivadas de globulos rojos (rmp) y metodos de uso.

Info

Publication number
MX2019006354A
MX2019006354A MX2019006354A MX2019006354A MX2019006354A MX 2019006354 A MX2019006354 A MX 2019006354A MX 2019006354 A MX2019006354 A MX 2019006354A MX 2019006354 A MX2019006354 A MX 2019006354A MX 2019006354 A MX2019006354 A MX 2019006354A
Authority
MX
Mexico
Prior art keywords
composition
rmp
methods
rmps
disclosure provides
Prior art date
Application number
MX2019006354A
Other languages
English (en)
Inventor
S Ahn Yeon
Jy Wenche
L Horstman Lawrence
Pamukcu Rifat
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of MX2019006354A publication Critical patent/MX2019006354A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La descripción proporciona una composición que comprende micropartículas derivadas de glóbulos rojos (RMP) que demuestran características clínicamente ventajosas.
MX2019006354A 2016-11-30 2017-11-29 Composicion de microparticulas derivadas de globulos rojos (rmp) y metodos de uso. MX2019006354A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662428155P 2016-11-30 2016-11-30
PCT/US2017/063700 WO2018102409A2 (en) 2016-11-30 2017-11-29 Rmp composition and methods of use

Publications (1)

Publication Number Publication Date
MX2019006354A true MX2019006354A (es) 2019-10-21

Family

ID=62241842

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006354A MX2019006354A (es) 2016-11-30 2017-11-29 Composicion de microparticulas derivadas de globulos rojos (rmp) y metodos de uso.

Country Status (21)

Country Link
US (1) US11241457B2 (es)
EP (1) EP3548092B1 (es)
JP (2) JP2020508963A (es)
KR (2) KR20190099436A (es)
CN (1) CN110799199B (es)
AU (1) AU2017367084B2 (es)
BR (1) BR112019010981A2 (es)
CA (1) CA3045144A1 (es)
DK (1) DK3548092T3 (es)
ES (1) ES2924134T3 (es)
HR (1) HRP20220892T1 (es)
HU (1) HUE059678T2 (es)
IL (1) IL266957B (es)
LT (1) LT3548092T (es)
MX (1) MX2019006354A (es)
PL (1) PL3548092T3 (es)
PT (1) PT3548092T (es)
RS (1) RS63537B1 (es)
RU (1) RU2768743C2 (es)
SI (1) SI3548092T1 (es)
WO (1) WO2018102409A2 (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US5332578A (en) 1989-04-14 1994-07-26 Prp, Inc. Platelet membrane microparticles
NZ279555A (en) * 1994-02-14 1998-01-26 Kirin Brewery Thrombopoietin polypeptides their production and use
US5690963A (en) 1995-06-30 1997-11-25 The United States Of America As Represented By The Secretary Of The Navy Freeze dried red blood cells
CA2348781A1 (en) 1998-11-12 2000-05-25 Novolytics Inc. Compositions and methods for producing vascular occlusion
US20030040480A1 (en) 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US7294455B2 (en) * 2003-05-16 2007-11-13 The University Of North Carolina At Chapel Hill Fixed-dried platelets cross-linked to protein
US7811558B2 (en) 2004-08-12 2010-10-12 Cellphire, Inc. Use of stabilized platelets as hemostatic agent
US9155764B1 (en) * 2004-12-07 2015-10-13 University Of Miami Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding
JP5204490B2 (ja) 2004-12-07 2013-06-05 ユニバーシティー オブ マイアミ 出血の制御及び出血性疾患の治療のための止血剤としての細胞由来微粒子
US20080057505A1 (en) 2006-07-14 2008-03-06 Ping Lin Methods and compositions for detecting rare cells from a biological sample
EP2668262B1 (en) * 2011-01-28 2017-11-29 University of Miami Expanded utility of red cell-derived microparticles (rmp) for treatment of bleeding
US10004764B2 (en) 2013-11-07 2018-06-26 University of Pittsburgh—of the Commonwealth System of Higher Education Red blood cell membrane-derived microparticles and their use for the treatment of lung disease
WO2016141325A1 (en) 2015-03-04 2016-09-09 University Of Rochester Systemic and topical application of platelet microparticles to treat bleeding in trauma patients

Also Published As

Publication number Publication date
PL3548092T3 (pl) 2022-10-10
EP3548092A4 (en) 2021-01-27
IL266957A (en) 2019-07-31
US20190321406A1 (en) 2019-10-24
DK3548092T3 (da) 2022-08-01
CA3045144A1 (en) 2018-06-07
RS63537B1 (sr) 2022-09-30
KR20190099436A (ko) 2019-08-27
RU2019120008A (ru) 2021-01-13
RU2768743C2 (ru) 2022-03-24
BR112019010981A2 (pt) 2019-10-15
WO2018102409A3 (en) 2019-12-05
CN110799199A (zh) 2020-02-14
KR20240049569A (ko) 2024-04-16
ES2924134T3 (es) 2022-10-04
PT3548092T (pt) 2022-08-09
RU2019120008A3 (es) 2021-03-09
HUE059678T2 (hu) 2022-12-28
JP2020508963A (ja) 2020-03-26
AU2017367084A1 (en) 2019-06-20
LT3548092T (lt) 2022-10-10
WO2018102409A2 (en) 2018-06-07
EP3548092B1 (en) 2022-07-06
CN110799199B (zh) 2024-01-30
EP3548092A2 (en) 2019-10-09
AU2017367084B2 (en) 2023-11-23
JP2023017857A (ja) 2023-02-07
IL266957B (en) 2022-05-01
HRP20220892T1 (hr) 2022-10-14
SI3548092T1 (sl) 2022-10-28
US11241457B2 (en) 2022-02-08

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
IL272367A (en) Antibodies against CD39, compositions containing antibodies against CD39 and methods of using antibodies against CD39
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
MX2022003273A (es) Anticuerpos anti-tau y metodos de uso.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
EP3600325A4 (en) UNIQUE COMPOSITIONS AND PROCESSES
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
EP3478308A4 (en) CANNABIS-BASED COMPOSITION AND PROCESSES
EP3501509A4 (en) NEW NANO CAGE AND USE THEREOF
EP3161124A4 (en) Endophytes, associated compositions, and methods of use thereof
MA40579A (fr) Anticorps anti-cll-1 et immunoconjugués
EP3383917A4 (en) NOVEL ANTI-CLAUDIN ANTIBODIES AND METHODS OF USE
EP3134121A4 (en) Novel anti-rnf43 antibodies and methods of use
TWD171711S (zh) 端子
MX2019005322A (es) Composiciones de recubrimiento y metodos de uso de las mismas.
EP3436083A4 (en) NEW COMPOSITIONS AND METHODS
EP3189079A4 (en) Novel anti-mfi2 antibodies and methods of use
EP3464346A4 (en) ANTIBODIES, COMPOSITION AND KITS THEREFOR AND METHOD FOR USE THEREOF
MX2019010984A (es) Composiciones de sintecina y metodos de uso.
EP3204414A4 (en) Novel anti-nodal antibodies and methods of using same
EP3781687A4 (en) NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EP4285930A3 (en) Protein formulations